In the patients with NASH, soluble GPNMB concentrations in sera were higher compared with the patients with SS and soluble GPNMB is a promising biomarker and therapeutic target for the development and progression of NAFLD in obesity. The gene discussed is GPNMB; the disease is obesity due to melanocortin 4 receptor deficiency.